Technologies

Stämm’s Continuous Bioreactor Increases Antibody Productivity by up to 30x in European and American Pilots

  • by

​ Pilot runs in Europe and South America show breakthrough efficiency in monoclonal antibody production with unprecedented cost savings and scalability using Stämm’s bubble-free continuous laminar flow bioreactor: the Bioprocessor. SAN FRANCISCO, Jan. 15, 2025… Read More »Stämm’s Continuous Bioreactor Increases Antibody Productivity by up to 30x in European and American Pilots